The contract concerns profiling Immunoglobulin E autoantibodies in blood serum
Oncimmune, an autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, has announced a new contract with a global pharma company.
Following a successful pilot carried out for a major pharmaceutical company, Oncimmune has entered into an agreement for a major new project with the same customer, with a contract value of at least US$1.5m.
During the pilot project, Oncimmune was able to demonstrate that it can reliably profile Immunoglobulin E (‘IgE’) autoantibodies in blood serum using its high-throughput bead-based platform. The new project is expected to be delivered over the next six months, with the majority of the revenue therefore falling into FY2025.
Martin Gouldstone, CEO of Oncimmune said: “I am delighted that our scientific team has demonstrated our ability to measure IgE, which is much harder to detect in blood serum than other immunoglobulins, using our high-throughput platform.”
Oncimmune is a UK-based precision medicine company focused on analyzing immune interactions via autoantibody profiling. Collaborating with global pharmaceutical firms and CROs, Oncimmune aims to discover novel biomarkers to enhance targeted therapies for immune-mediated diseases, with its R&D facility in Dortmund, Germany.
